Our researchers have shown that a PET scan could allow doctors to identify those Hodgkin lymphoma patients who will have a good outcome following chemotherapy. Their findings mean that some could safely avoid additional radiotherapy and its associated late effects.
Scientists from the Cancer Research UK Manchester Institute recently joined a Europe-wide consortium to develop liquid biopsies. The project aims to validate blood-based biomarkers, such as circulating tumour cells and circulating tumour DNA, for routine clinical use.
In breast cancer research, Manchester studies have demonstrated the potential to predict progression for patients with an early form of the disease, and successfully used a new drug combination to target cancer cells in the lab.